ARS Pharmaceuticals
SPRY
61 hedge funds and large institutions have $114M invested in ARS Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 14 increasing their positions, 26 reducing their positions, and 16 closing their positions.
308% more call options, than puts
Call options by funds: $3.81M | Put options by funds: $933K
56% more capital invested
Capital invested by funds: $73.3M → $114M (+$41M)
11.63% more ownership
Funds ownership: 74.14% → 85.77% (+12%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 64 → 61 (-3)
19% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 16
46% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$8.42M |
| 2 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$8.41M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$5.15M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.15M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$4.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.44M |
| 2 |
Renaissance Technologies
New York
|
-$1.16M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.15M |
| 4 |
Morgan Stanley
New York
|
-$894K |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$887K |
SPRY Hedge Fund Activity: Q3 2022 in Review
61 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q3 2022, worth a combined $114M — up 56% from $73.3M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of SPRY and 13 opened new positions — a net loss of 3 holders — while 26 trimmed existing stakes and 14 added.
The largest buyer was Rubric Capital Management (New York), adding an estimated $8.42M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $2.44M sold.
- 61 institutional investors held ARS Pharmaceuticals (SPRY) as of Q3 2022, down from 64 in Q2 2022.
- Funds reported $114M of ARS Pharmaceuticals stock for Q3 2022, up 56% quarter-over-quarter.
- 13 funds opened new ARS Pharmaceuticals positions in Q3 2022 and 16 closed out, a net change of -3 holders.
- The largest ARS Pharmaceuticals buyer in Q3 2022 was Rubric Capital Management (New York), an estimated $8.42M added.
- The largest ARS Pharmaceuticals seller in Q3 2022 was EcoR1 Capital, an estimated $2.44M sold.
Based on aggregated 13F filings for Q3 2022.